Exhibit 99.1

Quintiles Reports Third Quarter 2013 Results

• Net new business wins over $1.3 billion, up 29% compared to third quarter 2012; Backlog of $9.6 billion at the end of third quarter 2013
• Third quarter diluted adjusted EPS of $0.54 and adjusted net income of $71.9 million, up 20.0% and 36.7%, respectively, compared to third quarter 2012
• Third quarter GAAP reported diluted EPS of $0.50 and GAAP reported net income of $66.8 million, up 13.6% and 28.2%, respectively, compared to third quarter 2012
• Raised full year 2013 adjusted diluted EPS guidance to $2.03 - $2.09 per share
• Board authorized $125 million equity repurchase program

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--October 31, 2013--Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE:Q) today reported its financial results for the quarter ended September 30, 2013.

For the three months ended September 30, 2013, the Company’s growth in service revenues, excluding the impact of foreign currency fluctuations (“constant currency revenue growth”), was 4.0%, or $36.9 million compared to the same period last year. At actual foreign exchange rates, service revenues grew $19.1 million or 2.1% to $932.7 million compared to the same period last year including an unfavorable foreign currency impact of 1.9%, or $17.8 million. Constant currency revenue growth resulted from growth in the Product Development segment partially offset by a decrease in the Integrated Healthcare Services segment.

Adjusted income from operations was $132.5 million in the third quarter of 2013, representing growth of 20.4% compared to the prior year. The adjusted income from operations margin was 14.2%, representing 220 basis points of expansion compared to the same period last year. Adjusted net income was $71.9 million in the third quarter of 2013, representing growth of 36.7% compared to the same period last year. Diluted adjusted earnings per share was $0.54 in the quarter ended September 30, 2013, representing growth of 20.0% compared to the same period last year. Reported GAAP income from operations was $125.3 million, reported GAAP net income was $66.8 million and reported GAAP diluted earnings per share was $0.50 for the three months ended September 30, 2013. Reconciliations of the non-GAAP measures adjusted income from operations, adjusted net income and diluted adjusted earnings per share to the corresponding GAAP measures are attached to this press release.

Net new business grew 29% and 20% in the three and nine months ended September 30, 2013 to $1.34 billion and $3.60 billion, respectively compared to the same periods last year. The third quarter of 2013 was the fifth sequential quarter of $1.0 billion or more in net new business which has contributed to an ending backlog at September 30, 2013 of $9.6 billion. The book to bill ratio, which represents net new business divided by service revenues during the respective period, was 1.44 for the third quarter 2013 and 1.28 for the nine month period ended September 30, 2013.

“We are pleased with our financial results for the third quarter. We continue to gain market share as reflected in the strength of our net new business and the largest backlog in the industry,” said Tom Pike, Quintiles’ chief executive officer. “It is an indication that our strategy and solutions are relevant to our customers as they address the opportunities and challenges of the changing healthcare landscape. We have further differentiated our service offerings with the acquisition of Novella Clinical in the third quarter, strengthening our capabilities focused on emerging biopharma, oncology and medical devices.”

“We have delivered income from operations margin expansion sequentially and year over year within our Product Development segment while improving the performance of our Integrated Healthcare Services segment as demonstrated by the strong new business wins during the quarter and continued income from operations margin improvement compared to the first quarter of 2013. Our ending cash position improved with the strong cash generated from operations during the quarter. We continue to invest in growth areas of our business to bolster our scientific, therapeutic and data analytics expertise and we are confident that our focus of delivering value to customers translates into value creation for our shareholders.”

The Product Development segment net new business grew 9% for the current quarter and 18% for the nine months ended September 30, 2013 compared to the same periods last year which translates into a book to bill of 1.21 for the third quarter and 1.31 for the nine month period ended September 30, 2013. Product Development’s constant currency revenue growth was 6.3%, or $42.4 million during the third quarter of 2013 compared to the same period last year. At actual foreign exchange rates, Product Development’s service revenues grew 5.5% compared to the same period last year to $714.2 million. The constant currency revenue growth resulted from a volume related increase in core clinical services and global labs partially offset by the continuing wind down of a few large projects. Product Development’s income from operations margin was 19.7% for the third quarter, improving 180 basis points compared to the same period last year.

The Integrated Healthcare Services segment net new business grew 93% for the current quarter and 30% for the nine month period ended September 30, 2013 compared to the same periods last year which translates into a book to bill of 2.19 for the third quarter and 1.20 for the nine months period ended September 30, 2013. On a constant currency basis, Integrated Healthcare Services’ service revenues declined 2.3% or $5.5 million during the third quarter of 2013 compared to the same period last year primarily due to lower new business from the first half of 2013 and negative scope modifications and cancellations. At actual foreign exchange rates, Integrated Healthcare Services’ service revenues declined 7.6%, or $17.9 million, compared to the same period last year to $218.5 million of which $12.4 million or 5.3% was due to unfavorable foreign currency fluctuations. Integrated Healthcare Services’ income from operations margin was 5.3% for the third quarter, improving 10 basis points compared to the same period last year.

General corporate and unallocated expenses were $19.8 million during the third quarter compared to $24.9 million for the same period last year.

Interest expense was $28.8 million during the third quarter compared to $33.5 million for the same period last year.

The GAAP effective income tax rate was 29.1% for the third quarter of 2013 compared to 29.7% for the same period in 2012. The effective income tax rates for the three and nine month periods ended September 30, 2013 were positively impacted by the Company asserting in the second quarter of 2013 that the undistributed earnings of most of the Company’s foreign subsidiaries are indefinitely reinvested outside of the United States.

For the nine months ended September 30, 2013, the Company’s constant currency service revenue growth was 4.2% or $114.0 million compared to the same period in 2012. At actual foreign exchange rates, the Company’s service revenues of $2.8 billion grew 2.1% compared to the same period in 2012, which included an unfavorable foreign currency impact of 2.1% or $56.2 million. Adjusted income from operations for the nine months ended September 30, 2013 was $374.9 million, representing growth of 13.3% and 140 basis points of margin expansion compared to the same period last year. Adjusted net income was $192.5 million for the nine months ended September 30, 2013, representing growth of 19.8% compared to the same period last year. Diluted adjusted earnings per share was $1.53 for the nine months ended September 30, 2013, representing growth of 12.5% compared to the same period last year. Reported GAAP income from operations was $335.3 million, reported GAAP net income was $153.6 million and reported GAAP diluted earnings per share was $1.22 for the nine months ended September 30, 2013.

Recent Events

On October 30, 2013 the Company's Board of Directors approved an equity repurchase program authorizing the repurchase of up to $125 million of either the Company's outstanding shares or vested in-the-money employee stock option awards. The Company intends to use cash on hand to fund the program. The program does not obligate the Company to acquire any particular amount of common stock or stock options, and may be modified, extended, suspended or discontinued at any time. The program does not have an end date.

Financial Guidance

The Company has updated its full year 2013 guidance, which includes service revenues between $3.77 billion and $3.80 billion, representing an expected constant currency growth range of 4.1% to 4.9%, and raised diluted adjusted earnings per share to $2.03 and $2.09 per share, representing growth of 14.7% to 18.1% with diluted GAAP earnings per share between $1.71 and $1.77 per share. The Company has also updated the full year 2013 annual effective income tax rate to approximately 30%. This financial guidance is based on the actual results for the first nine month period of 2013 combined with the expected results for the last quarter of 2013, assuming the September foreign currency exchange rates stay in effect for the remainder of the year and includes the projected impact of the Novella acquisition. The guidance does not reflect the potential impact of any repurchases the Company may make pursuant to our equity repurchase plan.

Webcast & Conference Call Details

Quintiles will host a conference call at 8:00 a.m. EDT today to discuss its third-quarter 2013 financial results. To participate, please dial +1 (855) 484-7367 or +1 (631) 259-7541 outside the United States approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible, live via webcast, on the Investors section of the Quintiles website at www.quintiles.com/investors. An archived replay of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EDT on October 31, 2013.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of approximately 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Forward-Looking Statements

This press release contains forward-looking statements that reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, market trends or industry results to differ materially from those expressed or implied by such forward-looking statements. For this purpose, any statements contained herein that are not statements of historical fact may constitute forward-looking statements. Without limiting the foregoing, words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and the negative thereof and similar words and expressions are intended to identify forward-looking statements. Actual results may differ materially from the Company’s expectations due to a number of factors, including that most of the Company’s contracts may be terminated on short notice, and that the Company may be unable to maintain large customer contracts or to enter into new contracts; the historical indications of the relationship of backlog to revenues may not be indicative of their future relationship; the market for the Company’s services may not grow as the Company expects; the Company may under price contracts or overrun its cost estimates, and if the Company is unable to achieve operating efficiencies or grow revenues faster than expenses, operating margins will be adversely affected; the Company may be unable to maintain information systems or effectively update them; customer or therapeutic concentration could harm the Company’s business; the Company’s business is subject to risks associated with international operations, including economic, political and other risks such as compliance with a myriad of foreign laws and regulations, complications from conducting clinical trials in multiple countries simultaneously and changes in exchange rates; government regulators or customers may limit the scope of prescription or withdraw products from the market, and government regulators may impose new regulations affecting the Company’s business; the Company may be unable to successfully develop and market new services or enter new markets; the Company’s failure to perform services in accordance with contractual requirements, regulatory standards and ethical considerations may subject it to significant costs or liability, damage its reputation and cause it to lose existing business or not receive new business; the Company’s services are related to treatment of human patients, and it could face liability if a patient is harmed; the Company may be unable to successfully identify, acquire and integrate existing businesses, services and technologies; and the Company has substantial indebtedness and may incur additional indebtedness in the future, which could adversely affect the Company’s financial condition. For a further discussion of the risks relating to the Company’s business, see “Risk Factors” section in the final prospectus dated May 8, 2013 filed with the Securities and Exchange Commission relating to the Company’s initial public offering and the Company’s quarterly reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Use of Non-GAAP Financial Measures

This press release includes adjusted EBITDA, adjusted income from operations, adjusted income from operations margin, adjusted net income and diluted adjusted earnings per share, each of which is a financial measure not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Management believes that these non-GAAP measures provide useful supplemental information to management and investors regarding the underlying performance of the Company’s business operations and are more indicative of core operating results as they exclude certain items whose fluctuations from period-to-period do not necessarily correspond to changes in the core operations of the business. These non-GAAP measures are performance measures only and are not measures of the Company’s cash flows or liquidity, nor are they alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Investors and potential investors are encouraged to review the reconciliations of the non-GAAP financial measures to their most directly comparable GAAP measures attached to this press release.

Internet Posting of Information: The Company routinely posts information that may be important to investors in the 'Investors' section of the Company’s website at www.Quintiles.com. The Company encourages investors and potential investors to consult the Company’s website regularly for important information about the Company.

Click here to subscribe to Mobile Alerts for Quintiles.

CONTACT:
Quintiles
Phil Bridges, 919-998-1653
Media Relations
phil.bridges@quintiles.com
Mobile: 919-457-6347
or
Karl Deonanan, 919-998-2789
Investor Relations
InvestorRelations@quintiles.com